Project information

From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

Project Identification
MSM0021622434
Project Period
1/2007 - 12/2013
Investor / Pogramme / Project type
Ministry of Education, Youth and Sports of the CR
MU Faculty or unit
Faculty of Medicine
Keywords
multiple myeloma; proteomics; genomics

Monoclonal gammapathies and multiple myeloma in particular are among the most common and debilitating malignancies in the elderly population. In the last decade, there have been dramatic developments in basic and applied research in the field. New treatments have become available and treatment standards have changed. Treatment results have substantially improved and the probability of 10-year survival increased from 5% to 20% in the last decade. However, the disease is still incurable. The treatment strategy today includes potentially 3-5 regimens administered over a period of 10 to 15 years. There is increased tendency to apply treatment specifically tailored for a subgroup of patients with a well-defined risk and response rate.

Publications

Total number of publications: 315


Previous 1 2 3 4 5 6 7 32 Next